Screener
Assembly Biosciences ASMB Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Assembly Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211987
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liabilities - short-term | 590 | 569 |
| Total current liabilities | 34,997 | 48,780 |
| Operating lease liabilities - long-term | 1,901 | 2,059 |
| Total liabilities | 36,898 | 50,839 |
| Commitments and contingencies | ||
| Stockholders' equity | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding | — | — |
| Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 15,892,353 and 15,855,329 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 16 | 16 |
Item 1. Financial Statements
FAQ
- What is Assembly Biosciences's total liabilities?
- Assembly Biosciences (ASMB) reported total liabilities of $36.9M in Q1 2026.
- How has Assembly Biosciences's total liabilities changed year-over-year?
- Assembly Biosciences's total liabilities decreased by 48.7% year-over-year, from $71.88M to $36.9M.
- What is the long-term trend for Assembly Biosciences's total liabilities?
- Over 5 years (2020 to 2025), Assembly Biosciences's total liabilities has grown at a 3.6% compound annual growth rate (CAGR), from $42.68M to $50.84M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Assembly Biosciences's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude